Posted by Michael Wonder on 19 May 2020
China approves Austedo for treating chorea associated with Huntington's disease and tardive dyskinesia in adults
18 May 2020 - Teva Pharmaceutical Industries today announced that the China National Medical Products Administration has approved Austedo (deutetrabenazine tablets) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults, after a priority review.
China is the second country in the world after the U.S. to have approved Austedo.
